Paolo A. Ascierto
Italian melanoma oncologist who co-led CheckMate 238, CheckMate 067 and the COLUMBUS BRAF/MEK trial.
Overview
Paolo Ascierto has been a lead investigator on most of the pivotal melanoma trials of the past decade, including CheckMate 238 (adjuvant nivolumab), CheckMate 067, COLUMBUS (encorafenib plus binimetinib) and the CheckMate 915 and RELATIVITY programmes. He founded the Melanoma Bridge and Immunotherapy Bridge meetings and leads one of Europe's largest melanoma units in Naples.
| Title | Journal | Year |
|---|---|---|
| Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma (CheckMate 238): 4-year results | Lancet Oncology | 2020 |
| Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS) | Lancet Oncology | 2018 |
Pages like this
not linked directly; found by shared links- PersonCaroline Robert
Shares BRAF, Ipilimumab, Nivolumab, PD-1 and the tags melanoma, immunotherapy.
- PersonMichael A. Postow
Shares CheckMate 067, Ipilimumab, Nivolumab, PD-1 and the tags melanoma, immunotherapy.
- PersonJedd D. Wolchok
Shares CheckMate 067, Ipilimumab, Nivolumab, PD-1 and the tags melanoma, immunotherapy.
- PersonReinhard Dummer
Shares COLUMBUS, Encorafenib, BRAF, Small-molecule kinase inhibitors and the tag melanoma.
- PersonGeorgina V. Long
Shares BRAF, Ipilimumab, Nivolumab, PD-1 and the tag melanoma.
- PairingImmunotherapy first, then BRAF/MEK (BRAF-mutant melanoma)
Shares Encorafenib, BRAF, Ipilimumab, Nivolumab.
- ProductBinimetinib
Shares COLUMBUS, Encorafenib, BRAF, Small-molecule kinase inhibitors.
- PersonDirk Schadendorf
Shares CheckMate 067, Melanoma and the tags melanoma, immunotherapy.